About Us
OUR MISSION
To improve the lives of our patients by offering them access to effective and verified pharmaceutical treatments in the convenient dosage form.
Who we are
Auxilius Pharma is an emerging specialized pharmaceutical company with a focus on further developing and optimizing medications well established in some markets but not in the others, for the benefit of patients and to address major unmet needs in an increasingly cost conscious health care market environment. We are a versatile team with multifunctional healthcare experience in both the US and EU. We feature diverse backgrounds and strong core competencies in pharmaceutical marketing, drug development, pharmacology, health care management, corporate finance, and asset management.
What we do
We analyze various pharmaceutical sectors across European and American markets for drugs in therapeutic areas of high unmet clinical need, with high commercial potential and great disease management impact that have been underperforming or marginalized by blockbuster products. We pay particular attention to compounds that are underutilized because of their outdated formulation and seek to innovatively improve their dosing and application for the benefit of adherence and patient comfort. As such, we are focused mainly on a Generic Plus strategy as it combines relatively low capex and market risk with still promising sales potential. Generic Plus strategies attempt to enhance generic medications by reformulation to simplify dose strength, dose frequency or delivery route.
Team
Operational
Jed Litwiniuk, MHA
CEO
Read about
Pharmaceutical and Healthcare Executive and Corporate Finance Professional with over 15 years of experience on both sides of the Atlantic. Before co-founding Auxilius Pharma Jed worked for a range of institutions investing in the healthcare space. His experience includes roles such as head of M&A of Lux Med (the largest healthcare provider in CEE), Investment Director at Enterprise Venture Fund and PZU (the largest CEE insurance group). CEO of orthopedics and spine surgery inpatient clinic (CM Gamma). Co-founder of Picket Pharmaceuticals, NYC based start-up. In 2019 Jed gained Executive Master of Health Administration degree at Columbia University Mailman School of Public Health and focused his work on developing Auxilius Pharma
Uwe Tigör, MD
CMO
Read about
Extensive marketing and product launch experience as Chief Medical Officer and Medical Director in healthcare marketing and communications agencies from IPG, WPP, HAVAS Health to InventivHealth; consultant to Pharmaceutical Industry. Medical training in EU and US, MD from Humboldt University, Berlin. Cardiovascular research experience including a research fellowship at Mount Sinai Hospital, NY. MHA candidate at Columbia University Mailman School of Public Health
Dawid Chabowski, PhD
Science and Operational Manager
Read about
Trained biomedical scientist with experience in basic science research in areas of cardiovascular physiology, microvascular function and lipid signaling. With research experiences from institutions such as St. John’s University, Wake Forest University, and Mayo Clinic, he received his PhD from the Department of Pharmacology and Toxicology at the Medical College of Wisconsin
Pascal St-Laurent
Pharmaceutical Development Consultant
Read about
Experienced analytical chemist and manager with over 25 years of experience in research and development and quality assurance. Extensive knowledge of dissolution method development and validation (USP I, II, III and IV). Member of the USP's Performance Verification Testing Standard Expert Panel until 2025. Graduated from Concordia University (Montreal) with a Bachelors of Science, Specialization Chemistry.
Prior experiences include J&J Consumer Healthcare, Cephalon, Wyeth Pharmaceuticals, Schering and Merck
Anthony Grenier
Tech Transfer / CMC Consultant
Read about
Anthony Grenier is an independent technology transfer and outsourcing consultant. A chemical engineer by training, he has completed over 60 technology transfers for both large, public multinational corporations and small specialty or virtual pharma companies spanning all major segments of the life sciences industry. His key expertise is to help small virtual pharma companies to navigate efficiently through all the CMC activities leading to drug approval.
Len S. Smith
Chief IP Counsel
Read about
Over 20 years crafting and carrying out strategies for transactions and operations relating to innovative technologies and products. Structuring and negotiating technology, financing, and corporate deals, and other contracts; board, regulatory compliance, IP strategy. Formerly of Valeant, Medicis & Novo Nordisk. Mr. Smith holds a J.D. with honors from Washington University, undergraduate and graduate level technical degrees in biology, environmental science, and information systems management. Mr. Smith also completed internships with the Office of the Vice President of the United States, the U.S. Patent and Trademark Office, and the U.S. District Court for the Southern District of Illinois
Advisors
Profs. Juan Kaski
Medical Advisor
Read about
Professor Juan-Carlos Kaski, DSc, MD, DM (Hons), FRCP, FESC, FHFA, FRSM, FACC, FAHA
Professor Kaski is Professor of Cardiovascular Science (Emeritus), St Gorge’s, University of London, UK, and a Past-Director of the Cardiovascular and Cell Sciences Research Institute at St George’s, University of London, United Kingdom. He is also Honorary Consultant Cardiologist at St George’s University Teaching Hospitals, NHS Trust and the Royal Brompton Hospital in London, UK.
Prof Kaski is Chairman of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy, Deputy Editor of the European Heart Journal, Editor-in-Chief of European Cardiology Review Journal and Editor of the European Society of Cardiology Handbook on Cardiovascular Pharmacotherapy.
JC Kaski is Fellow/Member of over 30 scientific societies worldwide, Doctor Honoris Causa of several universities, a recipient of the Gold Medal of the Spanish Society of Cardiology, and a past-President of the International Society of Cardiovascular Pharmacotherapy (ISCP)
Prof Kaski’s research areas include microvascular and vasospastic angina, pathogenesis of angina, inflammatory and immunological mechanisms of atherosclerosis, and biomarkers of cardiovascular risk. He has authored over 600 scientific papers on these topics in peer review journals and 13 books on cardiovascular topics.
Prof Kaski is Chairman of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy, Deputy Editor of the European Heart Journal, Editor-in-Chief of European Cardiology Review Journal and Editor of the European Society of Cardiology Handbook on Cardiovascular Pharmacotherapy.
JC Kaski is Fellow/Member of over 30 scientific societies worldwide, Doctor Honoris Causa of several universities, a recipient of the Gold Medal of the Spanish Society of Cardiology, and a past-President of the International Society of Cardiovascular Pharmacotherapy (ISCP)
Prof Kaski’s research areas include microvascular and vasospastic angina, pathogenesis of angina, inflammatory and immunological mechanisms of atherosclerosis, and biomarkers of cardiovascular risk. He has authored over 600 scientific papers on these topics in peer review journals and 13 books on cardiovascular topics.
Prof. Michael Weber
Cardiology Advisor
Read about
Dr Michael Weber is a Professor of Medicine at Downstate College of Medicine of the State University of New York. He received his medical degree from Sydney University in Australia. His career has focused largely on hypertension and preventive cardiology. He has also been very much involved with new drug development going back to the beta blockers and through to the contemporary angiotensin receptor blockers.
He is an author of over 500 articles in the peer-reviewed literature and has authored or edited 16 books. He was a founder of the American Society of Hypertension (ASH) and the ASH Hypertension Clinical Specialists Accreditation Program and has served as President of both those organizations
Giora Davidai, MD
Medical Advisor
Read about
27 Years in pharmaceutical industry with experience from molecule to market (R&D to Medical Affairs) in senior positions. Worked on
CV. CNS, Metabolic and Respiratory drug development. Worked in GlaxoWellcome (GW), Boehringer Ingelheim, where he served as Executive Director and Head of the Cardiovascular, Metabolic, CNS and Pulmonary , and CMO AIT (Beyond Air).
Pediatric Nephrologist in Academic Medicine Centers, last at Duke University. Giora has received his MD qualification at Sackler School
of Medicine at Tel Aviv University
Tomasz H. Zastawny, PhD, DSc
Strategic Advisor
Read about
Chief Drug Development Officer - Americas at Parexel. Seasoned life science executive and scientist with over 25 years of experience in the pharmaceutical, biotechnology, diagnostics, and medical device industries. He has excelled in creating and executing global product development strategies, resulting in the successful launch of several pharmaceutical products and medical devices, as well as numerous FDA, PMDA, and EMA breakthrough and orphan drug designation approvals.
Dr. Zastawny's notable positions include serving as Senior VP of Development at Rakuten, VP of Clinical Operations at Epizyme, Chief Development Officer at Adial Pharmaceuticals, and VP of Development and Clinical Operations at Aveo Oncology.
